Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of erlotinib plus temsirolimus in previously treated advanced non-small cell lung cancer
2009-017101-11Phase 2Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and temsirolimus in non-small cell lung cancer (NSCLC), sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoints: Maximum tolerated dose, Safety and tolerability and 1 more. Started Aug 2010; status: completed.
02
Drugs
erlotinibtemsirolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017101-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017101-11.